Financial Contrast: Lantheus Holdings (LNTH) and TrovaGene (NASDAQ:TROV)

Lantheus Holdings (NASDAQ: LNTH) and TrovaGene (NASDAQ:TROV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitabiliy, institutional ownership, risk, dividends and earnings.

Analyst Ratings

This is a summary of current recommendations for Lantheus Holdings and TrovaGene, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus Holdings 0 1 3 0 2.75
TrovaGene 1 0 2 0 2.33

Lantheus Holdings currently has a consensus target price of $18.75, suggesting a potential upside of 1.35%. TrovaGene has a consensus target price of $4.60, suggesting a potential upside of 458.93%. Given TrovaGene’s higher probable upside, analysts clearly believe TrovaGene is more favorable than Lantheus Holdings.

Institutional and Insider Ownership

66.3% of Lantheus Holdings shares are held by institutional investors. Comparatively, 15.2% of TrovaGene shares are held by institutional investors. 2.3% of Lantheus Holdings shares are held by company insiders. Comparatively, 7.4% of TrovaGene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Lantheus Holdings has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, TrovaGene has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.

Profitability

This table compares Lantheus Holdings and TrovaGene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lantheus Holdings 8.44% -37.47% 15.16%
TrovaGene -10,938.20% -162.31% -77.68%

Earnings & Valuation

This table compares Lantheus Holdings and TrovaGene’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Lantheus Holdings $317.61 million 2.18 $75.23 million $0.72 25.69
TrovaGene $355,623.00 71.68 -$35.52 million ($1.34) -0.61

Lantheus Holdings has higher revenue and earnings than TrovaGene. TrovaGene is trading at a lower price-to-earnings ratio than Lantheus Holdings, indicating that it is currently the more affordable of the two stocks.

Summary

Lantheus Holdings beats TrovaGene on 10 of the 13 factors compared between the two stocks.

About Lantheus Holdings

Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.

About TrovaGene

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.